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Abstract 
Phospholamban (PLN) p.Arg14del cardiomyopathy is characterized by a distinctly arrhythmogenic 
biventricular phenotype that can be predominantly left ventricular, right ventricular, or both. Our 
aim was to further elucidate distinct features of this cardiomyopathy with respect to the distribution 
of desmosomal proteins observed by immunofluorescence in comparison to desmosomal 
arrhythmogenic cardiomyopathy and co-existent genetic variants. We studied 8 explanted heart 
specimens from PLN p.Arg14del mutation carriers. Macro- and microscopic examination revealed 
biventricular presence of fibrofatty replacement and interstitial fibrosis. Five out of 8 (63%) of 
patients met consensus criteria for both arrhythmogenic right ventricular cardiomyopathy (ARVC) 
and dilated cardiomyopathy (DCM). In four cases, targeted NGS revealed one additional pathogenic 
variant and six variants of unknown significance. Immunofluorescence showed diminished junction 
plakoglobin signal intensity at the intercalated disks in 4/6 (67%) cases fulfilling ARVC criteria but 
normal intensity in both cases fulfilling only DCM criteria. Notably, the 4 cases with diminished 
junction plakoglobin were also those where an additional gene variant was detected. 
Immunofluorescence for two proteins recently investigated in desmosomal ACM, synapse-associated 
protein 97 and glycogen synthase kinase-3 beta, showed a distinct distributional pattern in 
comparison to desmosomal ACM. In 7/8 (88%) cases we observed both a strong synapse-associated 
protein 97 signal at the sarcomeres and no glycogen synthase kinase-3 beta translocation to the 
intercalated discs. Phospholamban p.Arg14del cardiomyopathy is characterized by a distinct 
molecular signature compared to desmosomal ACM, specifically a different desmosomal protein 
distribution. This study substantiates the idea that additional genetic variants play a role in the 
phenotypical heterogeneity. 
Key words 
phospholamban; arrhythmogenic cardiomyopathy; dilated cardiomyopathy; immunofluorescence; 
next-generation sequencing 
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Abbreviations 
ACM  Arrhythmogenic cardiomyopathy 
ARVC  Arrhythmogenic right ventricular cardiomyopathy 
DCM   Dilated cardiomyopathy 
IHC  Immunofluorescence 
LV   Left Ventricle/ventricular 
MAGUK  Membrane-associated guanylate kinase 
NGS  Next-generation sequencing 
PLN  Phospholamban 
RV  Right ventricle/ventricular 
SERCA  Sarcoplasmic reticulum Ca2+-ATPase  
SNP  Single nucleotide polymorphism 
VUS  Variant of unknown significance 
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1. Introduction 
The most common forms of cardiomyopathy, classified according to their phenotypic expression, are 
hypertrophic, dilated (DCM), and arrhythmogenic cardiomyopathy (ACM), but overlapping 
phenotypes are well recognized.1 ACM encompasses a broad spectrum of disease that includes the 
classical right-dominant form (arrhythmogenic right ventricular cardiomyopathy; ARVC), 
predominant left-sided involvement (also referred to as left-dominant arrhythmogenic 
cardiomyopathy; LDAC) and biventricular subtypes. Ventricular arrhythmias and an increased risk of 
sudden cardiac death are characteristic of all subtypes, particularly in the young and those active in 
sports.2 In ACM, the electrical instability exceeds the degree of LV dysfunction as compared to DCM.  
Most ACM-associated pathogenic variants are found in desmosomal genes, but non-desmosomal 
pathogenic variants have more recently also been identified.3, 4   
Following the identification of the non-desmosomal p.Arg14del (c.40_42delAGA) mutation in 
the PLN gene in a large subset of DCM and ACM patients, it has been shown that mutation carriers 
are at increased risk of malignant ventricular arrhythmias and severe heart failure and have an 
impaired prognosis from late adolescence.5-7 Histopathologically, the disease has been demonstrated 
to be characterized by biventricular fibrofatty replacement and interstitial fibrosis. Furthermore,  
PLN-containing aggregates that are concentrated in dense perinuclear aggresomes in cardiomyocytes 
were observed.8-10 Patients with PLN p.Arg14del cardiomyopathy may fulfil international DCM 
criteria11 and/or ARVC revised task force criteria.12 In a previous study, immunofluorescence analysis 
of biopsy samples revealed depressed or absent junction plakoglobin signal intensity at intercalated 
disks in the majority (71%) of cases fulfilling ARVC criteria, but this was seen in only one out of nine 
(11%) DCM cases.5  
In desmosomal ACM, recently synapse-associated protein 97 and glycogen synthase kinase-3 
beta were studied. Synapse-associated protein 97  is a membrane-associated guanylate kinase 
(MAGUK) involved in trafficking sodium and potassium channel subunits to the cell surface, which 
helps maintain normal cardiac ventricular resting membrane action potential. This PDZ-domain 
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containing protein was found to be consistently reduced in the ventricular myocardium of 
desmosomal ACM-patients, an effect that is independent of the specific causal mutation.13 Glycogen 
synthase kinase-3 beta is a ubiquitously expressed serine/threonine kinase that remains active in the 
resting state and is inactivated when stimulated by, e.g., the Wnt pathway. Asimaki et al.13 identified 
a small molecule (SB2) as an inhibitor of glycogen synthase kinase-3 beta because it rescued the ACM 
phenotype in a zebrafish model, thereby increasing canonical Wnt signaling. All the desmosomal 
human ACM cases investigated (20/20) showed an abnormal glycogen synthase kinase-3 beta 
immunoreactive signal at the intercalated disks.14 Expression of these proteins has not been studied 
in PLN p.Arg14del cardiomyopathy.  
Further elucidation of the distribution of desmosomal proteins and co-existent genetic 
variants in PLN p.Arg14del cardiomyopathy may help us to better understand the observed 
phenotypic heterogeneity and improve diagnosic- and treatment options.  In order to study this, 
histologic examination, immunofluorescence, next-generation sequencing (NGS) for additional 
cardiomyopathy-associated genetic variants and clinical evaluation according to consensus criteria 
for DCM11 and ARVC12 were performed in PLN p.Arg14del cardiomyopathy heart transplant cases. 
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2. Materials and Methods 
2.1 Clinical and pathological examination 
We evaluated eight explanted hearts from index patients who were heterozygous carriers of the PLN 
p.Arg14del mutation from the Department of Pathology of the University Medical Center Groningen 
in the Netherlands. Information on gross examination of the hearts was available for all cases 
because they were evaluated during transplant procedures. Formalin-fixed and paraffin-embedded 
samples from, at minimum, the anterior, lateral and posterior wall of the left ventricle (LV), as well as 
the right ventricular (RV) wall, were available for all cases. Tissue sections (4 µm) were stained with 
hematoxylin and eosin as well as Masson’s trichrome. Tissue sections from the LV and RV were 
evaluated under light microscopy by recording the presence of myocyte hypertrophy and interstitial 
fibrosis and the presence of fibrofatty replacement. The presence of interstitial fibrosis in the LV wall 
was evaluated either as not present, present in the subepicardial half of the myocardial wall or 
transmurally present. The presence of fibrofatty replacement was evaluated by naked eye 
examination of Masson’s-trichrome-stained RV wall sections placed on a sheet of white paper.   
Clinical data of the eight Dutch index patients was collected from the PHORECAST registry 
(PHOspholamban RElated CArdiomyopathy STudy; http://www.phorecast.nl). The clinical criteria 
proposed by Mestroni et al.11 were used to diagnose DCM and the revised task force criteria to 
diagnose ARVC.12 
 
2.2 Ethics Statement 
The PHORECAST registry complies with the 'Code of conduct for medical research' drawn up by the 
Dutch Federation of Biomedical Scientific Societies (FMWV). The laws in force in the Personal Data 
Protection Act (WBP) and the Medical Treatment Contracts Act (WGBO) are incorporated in this code 
of conduct. This study met the criteria of the code of conduct for responsible use of human tissue 
that is used in the Netherlands (Dutch federation of biomedical scientific societies; 
http://www.federa.org). The study conformed to the principles of the Helsinki Declaration; all 
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material was originally obtained for diagnostic procedures and the tissue samples were de-identified 
before inclusion in the study.  
 
2.3 Gene variant analysis by targeted NGS 
Targeted NGS using a previously validated NGS method15 was performed for all eight PLN p.Arg14del 
mutation carriers to search for additional variants in 61 known cardiomyopathy-associated genes. 
Details of sample preparation, sequencing, data processing, and variant filtering and classification are 
summarized in the Supplementary File. American College of Medical Genetics and Genomics and 
Association for Molecular Pathology criteria were used for variant classification.16 Only variants of 
uncertain significance (VUS), likely pathogenic variants (LPV), or pathogenic variants (PV) were 
reported. 
 
2.4 Immunofluorescence 
Blinded patient samples were subjected to fluorescent immunofluorescence (IHC) as previously 
described.6, 17, 18 Tissue samples from age-matched individuals with no clinical or pathological 
evidence of heart disease were subjected to the same protocol and used as negative controls (n=5). 
Briefly, 4μm-thick formalin-fixed, paraffin-embedded tissue sections were deparaffinised, 
dehydrated, rehydrated and heated in citrate buffer (10 mmol/l, pH 6.0) to enhance specific 
immunofluorescence. After being cooled to room temperature, the tissue sections were 
simultaneously permeabilized and blocked by incubating them in phosphate-buffered saline 
containing 1% Triton X-100, 3% normal goat serum and 1% bovine serum albumin. The sections were 
then incubated, first with a primary antibody and then with indocarbocyanine-conjugated goat anti-
mouse or anti-rabbit rabbit IgG. The primary antibodies were the same as those used in previous 
studies: mouse monoclonal anti-N-cadherin (SIGMA), rabbit polyclonal anti-gap junction protein 
(SIGMA), mouse monoclonal anti-junction plakoglobin (SIGMA), mouse monoclonal anti-desmoplakin 
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(Fitzgerald), rabbit polyclonal anti-synapse-associated protein 97  (Santa Cruz Biotechnology) and 
rabbit polyclonal anti- glycogen synthase kinase-3 beta (Cell Signaling).17, 18 
  
3. Results 
3.1 Patient characteristics, clinical data and histopathology 
The eight explant heart specimens were from three males and five females with end-stage heart 
failure (mean[±SD] age 53±11 years; Table 1). Macro- and microscopic examination of the explanted 
heart specimens revealed features of both ARVC and DCM: biventricular presence of fibrofatty 
replacement that was most prominent in the RV wall and interstitial fibrosis that was most 
prominent in the subepicardial LV wall (Figure 1: case 5 as an typical example), as previously 
observed.8-10 Five out of 8 (63%) patients met consensus criteria for both ARVC and DCM. Two out of 
8 (25%) met consensus criteria for DCM only and one case for ARVC only (Table 1).  
 
3.2 Variant analysis 
Targeted NGS confirmed the pathogenic p.Arg14del mutation in PLN in all cases. In addition, one PV, 
no LPVs and 6 VUSs were found in cardiomyopathy-associated genes in four cases: emerin (EMD; one 
VUS), titin (TTN; three VUS, including two in one patient), myosin binding protein C (MYBPC3; one 
PV), troponin T (TNNT2; one VUS) and plakophilin2 (PKP2; one VUS). Details of the genetic variants 
are shown in Table 1. 
 
3.3 Immunofluorescence 
All cases showed a control signal similar in intensity and distribution for gap junction protein (the 
major cardiac gap junction protein normally located in the intercalated discs), desmoplakin, and N-
Cadherin (used as a tissue quality control). Junction plakoglobin signal intensity was depressed or 
absent at the intercalated disks in the majority (4/6; 67%) of cases fulfilling ARVC criteria, but signal 
intensity was normal at the intercalated disks in the two cases only fulfilling DCM criteria (Table 1).  
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Synapse-associated protein 97  immunofluorescence showed a strong signal at the 
sarcomeres in 7/8 (88%) cases, though the signal was gone from the intercalated disks (Table 1) as 
was observed previously in myocardial samples from patients with end-stage ischemic, dilated, or 
hypertrophic cardiomyopathy.13 Case 1, however, showed overall diminished signal intensity for 
Synapse-associated protein 97 (Figure 2) as previously shown in hearts from ACM patients with 
desmosomal gene mutations.13 
Immunofluorescence for glycogen synthase kinase-3 beta revealed that this protein retained 
its cytoplasmic distribution and did not translocate to the intercalated disks in the same 7/8 (88%) 
cases that showed a strong signal for synapse-associated protein 97 at the sarcomeres (Table 1). Case 
1 was the only case that showed junctional redistribution for glycogen synthase kinase-3 beta (Figure 
2), which is in contrast to what was seen in a desmosomal ACM cohort in which all 20 cases showed 
glycogen synthase kinase-3 beta junctional redistribution.14   
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4. Discussion 
In recent years the idea has emerged that pathogenic variants within a single specific 
cardiomyopathy-related gene may lead to several cardiomyopathy subtypes, i.e. phenotypic 
heterogeneity. A typical example of this phenomenon occurs in PLN p.Arg14del-related 
cardiomyopathy, where many symptomatic PLN p.Arg14del carriers have overlapping phenotypes 
and may fulfil international DCM criteria11 and/or ARVC revised task force criteria.12 LV involvement 
is typical in PLN p.Arg14del cardiomyopathy.3, 10, 19  
In line with previous findings in PLN p.Arg14del cardiomyopathy, we observed a biventricular 
phenotype with features of both ARVC and DCM. This challenges the strict distinction made between 
ARVC and DCM as two separate entities. The hearts showed biventricular presence of fibrofatty 
replacement and interstitial fibrosis, in line with our previous pathological8-10 and cardiac magnetic 
resonance imaging findings.20 Sepehrkhouy et al. recently showed this fibrosis pattern to be 
distinctive for PLN p.Arg14del cardiomyopathy in comparison with other hereditary 
cardiomyopathies.10 Clinically, the majority of patients (63%) in our cohort fulfilled criteria for both 
ARVC and DCM. Task force criteria are only available for ARVC12, but are not sufficient for LDAC.21 
Phospholamban p.Arg14del cardiomyopathy is a typical example of a biventricular ACM phenotype.  
Differential abnormalities in the distribution and expression of desmosomal and gap junction 
proteins have been reported in cardiac tissue of patients with ACM and DCM.17 Previous 
immunofluorescence analysis of biopsy samples revealed depressed or absent junction plakoglobin 
signal intensity at intercalated disks in the majority (71%) of cases fulfilling ARVC criteria, but this was 
seen in only one out of nine (11%) DCM cases.5 Junction plakoglobin redistribution thus seemed to 
track with phenotype rather than genotype. Interestingly, López-Ayala et al.22 also saw no junction 
plakoglobin redistribution in a similar LDAC phenotype caused by a desmoplakin truncating variant. 
They postulated that different signaling pathways explain the different molecular signatures 
observed in LDAC and ARVC.22 We extended these previous findings using novel IHC markers to 
characterize selected protein distribution in LV myocardial tissue. Junction plakoglobin signal 
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intensity was depressed or absent at the intercalated disks in the majority (4/6; 67%) of our cases 
fulfilling ARVC criteria but signal intensity was normal at the intercalated disks in our two DCM cases, 
confirming the different molecular signatures of protein distribution patterns depending on the 
phenotype.  
Immunofluorescence stainings for synapse-associated protein 97 and glycogen synthase 
kinase-3 beta confirmed the distinct molecular signature of PLN p.Arg14del cardiomyopathy in 
comparison to desmosomal ACM: synapse-associated protein 97 was previously shown to be 
consistently reduced in the ventricular myocardium of desmosomal ACM patients, an effect that was 
independent of specific causal mutation.13 We observed this in only one case (case 1). In 7/8 (88%) 
cases, immunofluorescence for synapse-associated protein 97 showed a strong synapse-associated 
protein 97 signal at the sarcomeres, although this signal was gone from the intercalated disks. This 
pattern had previously been seen in myocardial samples from patients with end-stage ischemic, 
dilated, or hypertrophic cardiomyopathy.13 Immunofluorescence for glycogen synthase kinase-3 beta 
revealed that retained its cytoplasmic distribution and did not translocate to the intercalated disks in 
the same 7/8 (88%) cases that showed a strong signal for synapse-associated protein 97 at the 
sarcomeres. Case 1 is the only one that showed junctional redistribution for glycogen synthase 
kinase-3 beta. In a desmosomal ACM cohort, all cases (20 out of 20) showed glycogen synthase 
kinase-3 beta junctional redistribution.14 Importantly, glycogen synthase kinase-3 beta 
downregulates SERCA2a leading to an inability to normalize cytosolic Ca2+ in diastole.23 Therefore, 
the disturbed SERCA2a/PLN interaction and subsequent calcium homeostasis in PLN p.Arg14del 
cardiomyopathy may play a role in the differential molecular signature observed. These new findings 
are in line with the phenotypical heterogeneity observed in PLN p.Arg14del cardiomyopathy. 
Using targeted next-generation sequencing, we found that another gene variant (PV or VUS) 
was present in those cases with a diminished junction plakoglobin signal intensity at the intercalated 
disks (4/8; 50%). The pathogenic variant in MYBPC3 (case 5), a sarcomeric gene, had been observed 
previously in another ARVC case but this may be a chance finding.24 In case 1, where we observed an 
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overall diminished synapse-associated protein 97 signal intensity and junctional redistribution of 
glycogen synthase kinase-3 beta, a VUS in the EMD-gene encoding emerin was detected in addition 
to the pathogenic PLN p.Arg14del variant (Table 1). Emerin is a nuclear envelope protein implicated 
in regulating muscle- and heart-specific gene expression and nuclear architecture. Due to the specific 
localization of emerin to desmosomes in the heart,25 this variant may play a role in the different 
distribution we observed in this case. Although it is important to note that the use of NGS techniques 
results in the identification of an increasing numbers of genetic variants and, consequently, of 
patients with complex genotypes, when interpreting the pathogenicity of genetic variants in 
ACM/DCM-related genes, we must be aware that putative pathogenic variants can also be present in 
healthy controls, albeit less frequently.26 Moreover, mutations outside well-known cardiomyopathy 
genes not analyzed here may also play a role. The interpretation of these data and identification of 
disease-causing variants and possible modifiers therefore remains a challenge. 
To summarize and conclude, we have shown that PLN p.Arg14del cardiomyopathy has a 
distinct molecular signature in comparison to desmosomal ACM. It appears that the PLN p.Arg14del 
mutation does not by itself cause diminished junction plakoglobin at the intercalated disks, loss of 
synapse-associated protein 97 signal from the sarcomeres and junctional redistribution of glycogen 
synthase kinase-3 beta, as was shown in desmosomal ACM. Although limited by the small size of our 
cohort, this study substantiates the idea that additional genetic variants play a role in the 
phenotypical heterogeneity and in the differential protein distribution observed in PLN p.Arg14del 
cardiomyopathy. The highly arrhythmogenic overlapping phenotype and the pattern of biventricular 
subepicardial fibrosis and fatty infiltration supports the concept of ACM, i.e. biventricular subtypes. 
These distinct features characterize PLN p.Arg14del cardiomyopathy and provide further evidence 
for this disease as a biventricular disease entity within the ACM spectrum. 
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Figures (2) 
Figure 1. Midventricular transverse myocardial slice of case 5 showing extensive fatty infiltration of 
the RV myocardium, especially at the outer anterior wall (outflow tract), and fibrofatty replacement 
of the LV myocardium, especially posterolaterally. 
 
Figure 2. Immunofluorescence of left ventricular myocardial tissue (case 1, case 7, and control). 
Immunoreactive signals for desmoplakin and gap junction protein at intercalated discs are normal 
compared to control. N-cadherin is used as a tissue quality control and is normal in all samples. The 
synapse-associated protein 97 signal is overall depressed in case 1 compared to control and case 7. 
Glycogen synthase kinase-3 beta maintained its normal cytoplasmic distribution in case 7 (and 
control) but shows junctional redistribution in case 1. 
 
 
